Biogen to Study Higher Dose of Spinraza in Spinal Muscular Atrophy
18 September 2019 - 10:22PM
Dow Jones News
By Colin Kellaher
Biogen Inc. (BIIB) Wednesday said it will launch a new study to
evaluate whether a higher dose of Spinraza can provide greater
efficacy in the treatment of the neuromuscular disease spinal
muscular atrophy.
The Cambridge, Mass., biopharmaceutical company said it will
conduct the phase 2/3 study at 50 sites around the world, with a
projected enrollment of 126 patients of all ages.
Biogen said the trial will compare two loading doses of 50
milligrams 15 days apart followed by a maintenance dose of 28
milligrams every four months with the current FDA-approved program
of four loading doses with 12-milligram maintenance doses every
four months.
Spinal muscular atrophy is a rare genetic disease characterized
by a loss of motor neurons in the spinal cord and lower brain stem,
resulting in severe, progressive muscle atrophy and weakness.
Biogen licensed the global rights to develop, manufacture and
commercialize Spinraza from Ionis Pharmaceuticals Inc. (IONS),
which receives royalties on sales of the drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 18, 2019 08:07 ET (12:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Apr 2023 to Apr 2024
